Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A systematic review and meta‐analysis

Soeroto et al., Reviews in Medical Virology, doi:10.1002/rmv.2420
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 83% Improvement Relative Risk Hospitalization 87% Severe case 87% Case 76% Tixagevimab/c..  Soeroto et al.  META ANALYSIS c19early.org Favorstixagevimab/ci.. Favorscontrol 0 0.5 1 1.5 2+
38th treatment shown to reduce risk in May 2022
 
*, now with p = 0.000029 from 17 studies, recognized in 31 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 95 treatments. c19early.org
Meta analysis of 6 studies showing significantly lower COVID-19 cases, hospitalization, severity, and mortality with tixagevimab/cilgavimab prophylaxis.
Currently there are 17 tixagevimab/cilgavimab studies and meta analysis shows:
OutcomeImprovement
Mortality42% lower [16‑60%]
Ventilation96% higher [-82‑2060%]
ICU admission65% lower [-2078‑99%]
Hospitalization63% lower [39‑77%]
Cases69% fewer [11‑89%]
risk of death, 83.0% lower, OR 0.17, p = 0.047, RR approximated with OR.
risk of hospitalization, 87.0% lower, OR 0.13, p < 0.001, RR approximated with OR.
risk of severe case, 87.0% lower, OR 0.13, p < 0.001, RR approximated with OR.
risk of case, 76.0% lower, OR 0.24, p < 0.001, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Soeroto et al., 8 Jan 2023, peer-reviewed, 4 authors.
This PaperTixagev../c..All
{ 'indexed': {'date-parts': [[2024, 8, 1]], 'date-time': '2024-08-01T05:06:19Z', 'timestamp': 1722488779796}, 'reference-count': 51, 'publisher': 'Wiley', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2023, 1, 8]], 'date-time': '2023-01-08T00:00:00Z', 'timestamp': 1673136000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 3]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Some proportions of populations, such as ' 'immunocompromised patients and organ transplant recipients might have inadequate immune ' 'responses to the vaccine for coronavirus disease 2019 (COVID‐19). For these groups of ' 'populations, administering monoclonal antibodies might offer some additional protection. This ' 'review sought to analyze the effectiveness and safety of tixagevimab‐cilgavimab (Evusheld) as ' 'pre‐exposure prophylaxis against COVID‐19. We used specific keywords to comprehensively ' 'search for potential studies on PubMed, Scopus, Europe PMC, and <jats:ext-link ' 'xmlns:xlink="http://www.w3.org/1999/xlink" ' 'xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</jats:ext-link> sources until 3 ' 'September 2022. We collected all published articles that analyzed tixagevimab‐cilgavimab on ' 'the course of COVID‐19. Review Manager 5.4 was utilized for statistical analysis. Six studies ' 'were included. Our pooled analysis revealed that tixagevimab‐cilgavimab prophylaxis may ' 'decrease the rate of SARS‐CoV‐2 infection (OR: 0.24; 95% CI: 0.15–0.40, ' '<jats:italic>p</jats:italic>\xa0&lt;\xa00.00001, ' '<jats:italic>I</jats:italic><jats:sup><jats:italic>2</jats:italic></jats:sup>\xa0=\xa075%), ' 'lower COVID‐19 hospitalization rate (OR: 0.13; 95% CI: 0.07–0.24, ' '<jats:italic>p</jats:italic>\xa0&lt;\xa00.00001, ' '<jats:italic>I</jats:italic><jats:sup>2</jats:sup>\xa0=\xa00%), decrease the severity risk ' '(OR: 0.13; 95% CI: 0.07–0.24, <jats:italic>p</jats:italic>\xa0&lt;\xa00.00001, ' '<jats:italic>I</jats:italic><jats:sup>2</jats:sup>\xa0=\xa00%), and lower COVID‐19 deaths ' '(OR: 0.17; 95% CI: 0.03–0.99, <jats:italic>p</jats:italic>\xa0=\xa00.05, ' '<jats:italic>I</jats:italic><jats:sup>2</jats:sup>\xa0=\xa072%). In the included studies, no ' 'major adverse events were reported. This study proposes that tixagevimab‐cilgavimab was ' 'effective and safe for preventing COVID‐19. Tixagevimab‐cilgavimab may be offered to those ' 'who cannot be vaccinated or have inadequate immune response from the COVID‐19 vaccine to give ' 'additional protection.</jats:p>', 'DOI': '10.1002/rmv.2420', 'type': 'journal-article', 'created': {'date-parts': [[2023, 1, 9]], 'date-time': '2023-01-09T05:38:56Z', 'timestamp': 1673242736000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 22, 'title': 'Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A ' 'systematic review and meta‐analysis', 'prefix': '10.1002', 'volume': '33', 'author': [ { 'given': 'Arto Yuwono', 'family': 'Soeroto', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Internal Medicine Division of Pulmonology and ' 'Critical Illness Padjadjaran University Bandung West Java ' 'Indonesia'}]}, { 'given': 'Theo Audi', 'family': 'Yanto', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine Faculty of Medicine Pelita ' 'Harapan University Tangerang Indonesia'}]}, { 'ORCID': 'http://orcid.org/0000-0002-5219-9029', 'authenticated-orcid': False, 'given': 'Andree', 'family': 'Kurniawan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine Faculty of Medicine Pelita ' 'Harapan University Tangerang Indonesia'}]}, { 'ORCID': 'http://orcid.org/0000-0002-1748-9776', 'authenticated-orcid': False, 'given': 'Timotius Ivan', 'family': 'Hariyanto', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Medicine Pelita Harapan University Tangerang ' 'Indonesia'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 1, 8]]}, 'reference': [ { 'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jpsychires.2021.08.031'}, { 'key': 'e_1_2_10_3_1', 'unstructured': 'World Health Organization.Coronavirus Disease (COVID‐19): Situation ' 'Report;2022. Accessed September ' '1.https://www.who.int/publications/m/item/weekly‐epidemiological‐update‐on‐COVID‐19–‐31‐august‐2022'}, { 'key': 'e_1_2_10_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.archger.2020.104299'}, {'key': 'e_1_2_10_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41440‐020‐0515‐0'}, { 'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.diabres.2021.109031'}, { 'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.diabres.2022.110205'}, { 'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.yebeh.2021.108437'}, { 'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijcha.2020.100557'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMcp2009575'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm7030e2'}, { 'key': 'e_1_2_10_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2021.111272'}, {'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.52225/narra.v2i3.92'}, {'key': 'e_1_2_10_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.52225/narra.v2i3.88'}, {'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.27730'}, {'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.27623'}, { 'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13054‐020‐03400‐9'}, {'key': 'e_1_2_10_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.26698'}, { 'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/14787210.2021.1982695'}, {'key': 'e_1_2_10_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116620'}, {'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/ajt.17121'}, {'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofac283'}, { 'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ccell.2022.05.007'}, { 'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamasurg.2021.0546'}, {'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n71'}, { 'key': 'e_1_2_10_26_1', 'unstructured': 'National Health Commission of the People’s Republic of China.Diagnosis ' 'and Treatment of New Coronavirus Pneumonitis. (Trial Version ' '5).http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml'}, {'key': 'e_1_2_10_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.l4898'}, {'key': 'e_1_2_10_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/CLEP.S66677'}, {'key': 'e_1_2_10_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/ajt.17128'}, { 'key': 'e_1_2_10_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.kint.2022.05.007'}, { 'key': 'e_1_2_10_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.kint.2022.07.008'}, {'key': 'e_1_2_10_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciac625'}, { 'key': 'e_1_2_10_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2022.05.28.22275716'}, { 'key': 'e_1_2_10_34_1', 'unstructured': 'World Health Organization. Tracking SARS‐CoV‐2 variant. Accessed ' 'December 14 ' '2022.https://www.who.int/activities/tracking‐SARS‐CoV‐2‐variants'}, { 'key': 'e_1_2_10_35_1', 'unstructured': 'GÉODES.Géo Données En Santé Publique;2022. Accessed December ' '14.https://geodes.santepubliquefrance.fr'}, {'key': 'e_1_2_10_36_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2201570'}, { 'key': 'e_1_2_10_37_1', 'unstructured': 'Centers for Disease Control and Prevention.First Confirmed Case of ' 'Omicron Variant Detected in the United States;2022. Accessed December ' '14.https://www.cdc.gov/media/releases/2021/s1201‐omicron‐variant.html'}, { 'key': 'e_1_2_10_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s0895‐4356(99)00161‐4'}, {'key': 'e_1_2_10_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/sim.1461'}, { 'key': 'e_1_2_10_40_1', 'unstructured': 'United States Food and Drug Administration (FDA).FDA limits use of ' 'certain monoclonal antibodies to treat COVID‐19 due to the omicron ' 'variant.2022. Accessed December ' '14.https://ldh.la.gov/assets/oph/Center‐CP/HANs/2022/HANS22‐07‐FDALimitsUse‐Certain‐Monoclonal‐Antibodies‐Omicron‐Variant.pdf'}, {'key': 'e_1_2_10_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2119407'}, {'key': 'e_1_2_10_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/spectrum.00926‐22'}, { 'key': 'e_1_2_10_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.amjmed.2022.06.019'}, { 'key': 'e_1_2_10_44_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jiph.2022.11.024'}, { 'key': 'e_1_2_10_45_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40265‐022‐01731‐1'}, { 'key': 'e_1_2_10_46_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.abl8124'}, { 'key': 'e_1_2_10_47_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pmed.1003917'}, {'key': 'e_1_2_10_48_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2022.13214'}, { 'key': 'e_1_2_10_49_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104820'}, { 'key': 'e_1_2_10_50_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591‐022‐01792‐5'}, { 'key': 'e_1_2_10_51_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/diagnostics1106109'}, {'key': 'e_1_2_10_52_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.20‐1110'}], 'container-title': 'Reviews in Medical Virology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/rmv.2420', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/rmv.2420', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/rmv.2420', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T05:35:55Z', 'timestamp': 1711690555000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/rmv.2420'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 8]]}, 'references-count': 51, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2023, 3]]}}, 'alternative-id': ['10.1002/rmv.2420'], 'URL': 'http://dx.doi.org/10.1002/rmv.2420', 'relation': {}, 'ISSN': ['1052-9276', '1099-1654'], 'subject': [], 'container-title-short': 'Reviews in Medical Virology', 'published': {'date-parts': [[2023, 1, 8]]}, 'assertion': [ { 'value': '2022-11-15', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-12-26', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-01-08', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit